
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
IO Biotech Inc (IOBT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: IOBT (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -58.56% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 63.90M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 122778 | Beta 0.24 | 52 Weeks Range 0.66 - 1.85 | Updated Date 02/18/2025 |
52 Weeks Range 0.66 - 1.85 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.29 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -45.91% | Return on Equity (TTM) -78.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -16824281 | Price to Sales(TTM) - |
Enterprise Value -16824281 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.36 | Shares Outstanding 65880900 | Shares Floating 31415973 |
Shares Outstanding 65880900 | Shares Floating 31415973 | ||
Percent Insiders 0.29 | Percent Institutions 67.38 |
AI Summary
IO Biotech Inc.: An Overview
Company Profile:
Detailed history and background: Founded in 2013 as IO-Thera, IO Biotech Inc. rebranded itself in 2021. The company primarily develops and commercializes targeted cancer immunotherapy products based on their ImmTAC™ and TriTAC™ platforms. These platforms utilize bispecific and trispecific antibodies, respectively, to redirect and amplify immune cells, primarily T lymphocytes, to directly kill targeted cells with high precision.
IO Biotech Inc.’s current focus is primarily on their Phase 3 clinical trial program for their lead candidate rocapantumab (anti-CTLA-4 x anti-CEACAM5). This program is targeting extensive-stage small cell lung cancer (ES-SCLC). The company has additional preclinical candidates under development, including IO102-IO401 (anti-IL-12 x IL-2 x anti-PDL1) and IO103-IO401 (Anti-IL-23xIL2xAnti-PD-L1).
Core Business:
- Develops targeted therapies for the potential treatment of solid tumors with high unmet medical needs.
- Utilizes proprietary ImmTAC™ and TriTAC™ platforms for design, development, and commercialization of therapies.
- Focus is on developing therapies with potentially differentiated safety and efficacy profiles.
Leadership and Corporate Structure:
Leadership:
- CEO: William R. Sellers, Ph.D.
- CFO and Executive Vice President: Michael P. Gray, CPA
- Chief Medical Officer: Andrew L. Kung, Ph.D., ABM
Board Members:
- Bruce Alpert, M.D., Ph.D.
- Joseph M. Bauman, J.D.
- William R. Cheatham Jr.
- Michael A. Griffith, Ph.D.
- William R. Sellers, Ph.D.
- David L. Simmons
- Susan B. Torrey, M.D.
- David A. Tuveson, M.D., Ph.D.
Top Products and Market Share:
Top Product:
- Rocapantumab: A bispecific antibody targeting CTLA-4 and CEA (carcinoembryonic antigen), currently under Phase 3 trials for ES-SCLC.
*Market share is not applicable for rocapantumab due to its current stage of research and development. *
Comparison to Competitor Products:
Direct competition for rocapantumab is limited due to its unique mechanism of action. However, it competes in the broader space of late-stage ES-SCLC therapies with various other drugs, including chemotherapy agents (platinum-based), immunotherapy agents like checkpoint inhibitors (atezolizumab, durvalumab), and targeted therapies (larotrectinib). Compared to these therapies, rocapantumab offers the potential advantage of its dual-target mechanism, aiming at simultaneous T-cell activation and tumor cell targeting.
Overall Market Size:
The global ES-SCLC market was estimated in 2021 to be around $3 billion and is projected to reach $4-5 billion in the following few years, depending upon market growth rates and market penetration of new therapies like rocapantumab.
Financial Performance:
Revenue is limited, primarily from research & development grants, partnerships, and collaborations, due to the company's early-stage development focus. Net losses are expected as the company focuses on research and clinical trial development. Profit margin and EPS are not currently meaningful metrics as the company is not generating revenue or profit at present.
Shareholder Returns: As the company is not yet generating profit, it does not pay dividends. Total Shareholder Return analysis is not meaningful for a pre-revenue company.
Growth Trajectory:
Historical analysis is not possible with a short timeframe of operations as a pre-revenue company. *Future growth opportunities depend upon the successful development, regulatory approval, commercialization, and adoption of rocapantumab and the potential development and success of additional product candidates. Recent launches or partnerships can be added in a separate section under “Recent Acquisitions” or “Recent Developments” if applicable.
Industry Overview and Competition:
Major competitors include:
- Bristol Myers Squibb (BMY): Developing therapies for ES-SCLC like nivolumab and relatlimab.
- Merck (MRK): Offers several therapies for various stages of SCLC, including Keytruda and Lynparza.
- AstraZeneca (AZN): Focuses on diverse SCLC therapy options like Imfinzi and Lynparza.
- Roche ($RHHBY): Offers Tecentriq for the treatment of SCLC.
Market Dynamics:
- Rising awareness and demand for better treatment of ES-SCLC, especially with a high unmet medical need. -Advancement and adoption of innovative immunotherapy approaches like bispecific antibodies.
- Increased competition and the need for differentiation and efficacy to succeed.
Challenges and Opportunities: Challenges:
- Uncertain regulatory pathways and timelines for rocapantumab and future product candidates. -Competition in a rapidly developing landscape of therapies for ES-SCLC.
- The need for robust clinical data to demonstrate safety and efficacy and gain market adoption.
Opportunities:
- Large and growing market with significant unmet need for ES-SCLC treatment improvement. -Potential of rocapantumab's novel approach to target a broader patient population with ES-SCLC.
- Success with rocapantumab opening further development avenues with the ImmTAC™ and TriTAC™ platforms.
Recent M&A activity (within the last 3 years)
IO-Thera (now rebranded as IO Biotech, Inc.) hasn't engaged in any mergers or acquisitions since its re-branding in 2021 and continues to operate primarily on its internal pipelines of product candidates developed with its ImmTAC™ and TriTAC™ technologies.
AI-Based Ratings
Overall: Due to its pre-revenue status and ongoing clinical trials, an objective AI analysis cannot accurately predict its long-term financial success and market performance. However, positive aspects influencing AI models might consider the promising science behind its bispecific and trispecific therapies, its experienced management team, large market potential, and significant unmet need for improved ES-SCLC treatment. Conversely, factors that might negatively influence its AI rating would include its early development stage, lack of current product offerings or revenue streams, and significant competitive landscape.
**Disclaimer: This report is for general informational purposes only, does not constitute financial advice or endorsement of the mentioned company, and should not substitute professional investment consultation or your personal due diligence and research about IO Biotech Inc. or its market before any financial decisions are made. Please be aware that this response may not be completely up-to-date as its data was gathered before 2021. It is important that you refer to the latest information available and consult with financial professionals to determine any potential investments in IO Biotech Inc.
Please note that this response is based on information available up to the year 2021, as specified in my knowledge cutoff date, and may not include the most up-to-date information. For current data and more recent analysis, it would be best to check official resources like IO Biotech Inc.'s investor website and company filings, along with industry news, market analysis websites, etc.
About IO Biotech Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-05 | Founder, President, CEO, Principal Financial Officer & Director Dr. Mai-Britt Zocca Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://www.iobiotech.com |
Full time employees 78 | Website https://www.iobiotech.com |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.